Donal O’Shea

Professor Donal O’Shea

Artigo(s) publicado(s) :


 
Prof. Donal O’Sheal, MB, Bch, BAO, MD, FRCPI, FRCP (UK)

Endocrinology & Diabetes Mellitus Department

St. Vincent’s University Hospital

Elm Park

Dublin 4

 

Perfil de Carreira (Educação e Emprego)

 

Qualificações

1989 MB BCh BAO University College Dublin

1996 MD, Imperial College School of Science, Medicine and Technology, London

 

Detalhes de Empregos Actuais

Consultant Physician and Endocrinologist, St Vincent’s University Hospital and St Columcille’s HospitalDublin.

Associate Professor of Medicine, University College Dublin.

Head of the Obesity Research Group, Education and Research Centre, St Vincent’s University Hospital, Dublin

 

Distinções

  1. Auditor University College Dublin Medical Society.
  2. University College Dublin Medical Society President’s Prize
  3. UCD and Mater Hospital Leonard Prize in Medicine
  4. Wellcome Trust Research Training Fellowship
  5. Patrick M Meenan UCDMGA Inaugural Research Medal
  6. Norman Plummer Prize for Postgraduate Clinical Research
  7. Imperial College School of Medicine Undergraduate Teacher of the Year
  8. Irish Endocrine Society O’Donovan Medal for group’s research activity

2003-2008 & 2010 UCD Premier Award for Undergraduate Teaching Excellence

 

Financiamento de Revisão pelos Pares

– Cinco Newman Scholarships Awards de cientistas pós-doutorados através das Fundações UCD, 4 fundados por Sanofi-Aventis: Obesity, immune dysfunction and chronic inflammation. 2006-2008 (Dr. Lydia Lynch), 2008-2010 (Dr. Andrew Hogan), 2011-2013 (Dr. Conor Woods), 2013-2015 (Dr. Laura Tobin). Uma bolsa escolar foi fundada por Ipsen; 2011-2013 (Dr. Gaoatswe). Valor de 95.000€ cada.

Diabetes Federation of Ireland Health Research Board Project Grant 2006–2008. Tamanho do adipócito e diabetes tipo 2 na obesidade; um estudo de pacientes submetidos a uma cirurgia bariátrica. Valor de 181,000€.

Health Research Board Clinic Research Training Fellowship 2007–2009. Obesidade metabolicamente saudável e inflamação no tecido adiposo. Aplicante Dr. Jean O’Connell. Valor de 183.000€.

Irish Heart Foundation Project Grant, 2009-2011. Fumar e o desenvolvimento de diabetes. Valor de 234.756€

– Uso pediátrico SpR financiado por 2 anos para completar o MD no projecto financiado pela CRC. Valor de 120.000€

 

Investigação e Tutoria

Até agora, na minha carreira de investigação clínica tenho estabelecido um registo de publicação consistente nos domínios da obesidade e diabetes, com mais de 75 publicações até à data. Mais recentemente, o meu grupo de pesquisa tem publicado artigos sobre os efeitos imunológicos de que estas condições retratam.

Tenho até agora supervisionado 4 clínicos (Dr. Khatib, Dr. Abusnana, Dr. Cawood e Dr. O’Connell) na conclusão dos seus doutoramentos e 1 na conclusão do seu mestrado (Dr. Bashir). Tenho 4 clínicos registados para um doutoramento (Dr. Woods, Dr. Ahern, Dr. Gaoawste e Dra. Carolan) e 2 para um mestrado (Dr. Kattak e Dr. Armin). Dra. Eririn Carolan e o seu sucessor Dr. Meenal Mavinkurve, comprometeram-se na investigação de projetos da obesidade pediátrica em colaboração com Dr. Declan Cody de Our Lady’s Children’s Hospital. Com o Dr. Brian Kirby, tenho co-supervisionado um dermatologista (Dra. Anne Marie Tobin) no seu doutorado e com o Prof. Walter Mc Nicholas, tenho co-supervisionado o Dr. Brian Kent no seu doutorado. Ambos estiveram presentes e apresentaram os seus planos de avaliação/experiências na nossa reunião semanal. Tenho supervisionado duas dietistas na nossa unidade na conclusão do seu mestrado (Alison Quinn e Lorraine Cooney). Estou particularmente satisfeito pelo facto de outra das nossas dietistas, Cathy Breen, tirou algum tempo para tirar o seu doutorado. Ela completou a transferência do seu doutorado e está agora no ano final dos seus estudos, tendo 3 publicações baseadas no projeto do seu doutorado. Presentemente, tenho 3 cientistas pós-doutorados (Dr. Andrew Hogan, Dra. Michelle Corrigan e Dra. Laura Tobin). Os meus alunos atuais estão em vias da conclusão de um doutorado bem sucedido, com excelentes oportunidades para publicações.

 

Publicações

1.Ahern T, Khattak A, O’Malley E, Dunlevy C, Kilbane M, Woods C, McKenna MJ, O’Shea D.Association Between Vitamin D Status and Physical Function in the Severely Obese.J Clin Endocrinol Metab. 2014 Apr 15:jc 20141704.PMID:24735426.

2.Breen C, Ryan M, McNulty B, Gibney MJ, Canavan R, O’Shea D.High saturated-fat and low-fibreintake: a comparative analysis of nutrient intake in individuals with and without type 2 diabetes.Nutr Diabetes. 2014 Feb 3;4:e104. doi: 10.1038/nutd.2014.2.PMID: 24492470 [PubMed]Related citations

3.Carolan E, Hogan AE, Corrigan M, Gaotswe G, O’Connell J, Foley N, O’Neill LA, Cody D, O’Shea

  1. The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression.J Clin Endocrinol Metab. 2013 Jan 1:jc20133529. [Epub ahead of print]PMID: 24423308 [PubMed – as supplied by publisher]

4.Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O’Connell J, O’Shea D.Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.Diabetologia. 2013 Dec 21. [Epub ahead of print]PMID: 24362727 [PubMed – as supplied by publisher]

5.Breen C, Ryan M, Gibney MJ, Corrigan M, O’Shea D.Glycemic, insulinemic, and appetite responses of patients with type 2 diabetes to commonly consumed breads. Diabetes Educ. 2013 MayJun;39(3):376-86. Doi: 10.1177/0145721713479675. Epub 2013 Mar 12.

6.O’Shea D, Corrigan M, Dunne MR, Jackson R, Woods C, Gaoatswe G, Moynagh ON, O’Connell J,Hogan AE. Changes in Human dendritic cell number ans function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes (Lond). 2013 Feb 26;doi:1038/ijo. PMID 23439322.

7.Farah N, Hogan AE, O’Connor N, Kennelly MM, O’Shea D, Turner MJ.Correlation between maternal inflammatory markers and fetomaternal adiposity. Cytokine. 2012 Oct;60(1):96-9. Doi: 10.1016/j.cyto.2012.05.024. Epub 2012 Jun 20.

8.Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O’Shea D, O’FarrellyC, Exely MA. Adipose tissue invariant iNKT cells protect against diet-induced obesity and metabollic disorder through regulatory cytokine production. Immunity. 2012 Sept 21;37(3):547-87. PMID 22981538.

9.Macananey O, O’Shea D, Warmington SA, Green S, Egaña M.Gymnasium-based unsupervised exercise maintains benefits in oxygen uptake kinetics obtained following supervised training in type 2 diabetes. Appl Physiol Nutr Metab. 2012 Aug;37(4):599-609. Epub 2012 May 7.

10.O’Connor E, Kiely C, O’Shea D, Green S, Egaña M.Similar level of impairment in exerciseperformance and oxygen uptake kinetics in middle-aged men and women with type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2012 Jul 1;303(1):R70-6. Epub 2012 Apr 25.

11.Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O’Shea D. Glucagon-like- peptide1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2012 Jun 13 [Epub ahead of print]

12.Sahebally SM, Burke JP, O’Shea D, Geoghegan J.The effect of gastric band slippage on patient body mass index and quality of life. Obes Surg. 2012 May;22(5):773-6.

13.Hogan AE, Corrigan MA, O’Reilly V, Gaoatswe G, O’Connell J, Doherty DG, Lynch L, O’SheaD.Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses. Clin Immunol. 2011 Sep;140(3):229-35. Epub 2011 Feb 2.

14.Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, O’Reilly V, Lynch L,Doherty DG, Moynagh PN, Kirby B, O’Connell J, O’Shea D. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Diabetologia. 2011 Nov;54(11):2745-54. Epub 2011 Jul 9.

15.Sahebally SM, Burke JP, O’Shea D, Geoghegan J. The Effect of Gastric Band Slippage on PatientBody Mass Index and Quality of Life. Obes Surg. 2011 Oct 20. [Epub ahead of print] PMID:

16.Mac Ananey O, Malone J, Warmington S, O’Shea D, Green S, Egaña M.Cardiac output is not related to the slowed O2 uptake kinetics in type 2 diabetes. Med Sci Sports Exerc. 2011 Jun;43(6):935-42.

17.O’Connell J, Lynch L, Hogan A, Cawood TJ, O’Shea D.Preadipocyte factor-1 is associated with

metabolic profile in severe obesity. J Clin Endocrinol Metab. 2011 Apr;96(4):E680-4. Epub 2011 Jan 20.

18.Brogan A, Hevey D, O’Callaghan G, Yoder R, O’Shea D. Impaired decision making amongmorbidly obese adults.J Psychosom Res. 2011 Feb;70(2):189-96. Epub 2010 Nov 19.

19.Abbasakoor NO, Healy ML, O’Shea D, Maguire D, Muldoon C, Sheahan K, O’Toole D.Metastatic

insulinoma in a patient with type 2 diabetes mellitus: case report and review of the literature. Int J Endocrinol. 2011;2011:124078. Epub 2011 Feb 10.

20.MacAnaney O, Reilly H, O’Shea D, Egaña M, Green S.Effect of type 2 diabetes on the dynamic

response characteristics of leg vascular conductance during exercise. Diab Vasc Dis Res. 2011 Jan;8(1):12-21.

21.Judge EP, Phelan D, O’Shea D.Beyond statin therapy: a review of the management of residual risk indiabetes mellitus. J R Soc Med. 2010 Sep;103(9):357-62.

22.Cawood TJ, Bashir M, Brady J, Murray B, Murray PT, O’Shea D.Urinary collagen IV and pGST: potential biomarkers for detecting localized kidney injury in diabetes–a pilot study. Am J Nephrol. 2010;32(3):219-25. Epub 2010 Jul 20.

23.Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, Kirby B.Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010 Jul;37(7):138694. Epub 2010 May 15.

24.O’Connell J, Kieran P, Gorman K, Ahern T, Cawood TJ, O’Shea D. BMI > or = 50 kg/m2 is associated with a younger age of onset of overweight and a high prevalence of adverse metabolic profiles.Public Health Nutr. 2010 Jul;13(7):1090-8. Epub 2010 Jan 26.

25.Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE,Davies M.Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial; 1860LIRA-DPP-4 Study Group. Lancet. 2010 Apr 24;375(9724):1447-56.

Send this to a friend